<DOC>
	<DOC>NCT01580020</DOC>
	<brief_summary>The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the initial 6-month treatment in the respective core studies CRFB002EDE17 (NCT01396057) and CRFB002EDE18 (NCT01396083).</brief_summary>
	<brief_title>Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients must have completed the core study assessments at month 6 of study CRFB002EDE17 or CRFB002EDE18, respectively Patients who experienced an uncontrollable rise in IOP during the core study CRFB002EDE17 respectively CRFB002EDE18, i.e. IOP could not be decreased to a stable level of &lt; 25mmHg. Use of other investigational drugs Current use or likely need of systemic medications known to be toxic to the lens, retina or optic nerve History of hypersensitivity to Ranibizumab or Ozurdex or any component of the ranibizumab respectively Ozurdey formulation Any type of advanced, severe or unstable disease or its treatment, that could interfere with evaluations or put the patient at special risk Women who were pregnant or breast feeding (pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (&gt;5 mIU/mL) who were menstruating and capable of becoming pregnant* and not practicing a medically approved method of contraception (Pearl Index &lt;1**)*** during and up to at least 4 weeks after the end of treatment. A negative pregnancy test (serum) for all women and for girls entering menarche was required with sufficient lead time before randomization definition of postmenopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels &gt;40 mIU/mL or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy examples of particularly reliable methods with Pearl Index (PI) &lt;1, according to guidelines of "Deutsche Gesellschaft für Gynäkologie und Geburtshilfe": Combination pill with estrogen and gestagen (no minipill, PI=0.10.9) Vaginal ring (NuvaRing®, PI=0.65 uncorr.; 0.4 corr.) Contraceptive patch (EVRA®, PI= 0.72 uncorr.; 0.9 corr.) Estrogenfree ovulation inhibitors (Cerazette®, PI=0.14) Progestincontaining contraceptives (Implanon®, PI=00.08) Injectable 3month depot progestins (PI=0.31.4; 0.88 corr.) Intrauterine progestin device (Mirena®, PI=0.16)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Macular Degeneration</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Retinal Vein Occlusion</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>Signs and Symptoms</keyword>
	<keyword>Retinal Degeneration</keyword>
	<keyword>Retinal Diseases</keyword>
	<keyword>Eye Diseases</keyword>
	<keyword>Venous Thrombosis Sensation Disorders</keyword>
	<keyword>Dexamethasone acetate</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Dexamethasone 21-phosphate</keyword>
	<keyword>BB 1101</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Vision, Low</keyword>
	<keyword>Signs</keyword>
	<keyword>Vision Disorders</keyword>
</DOC>